PMPS Pain Phenotypes: Clinical Evidence from a Cancer Pain Clinic, 2022-2025

A retrospective analysis of 120 women with refractory post-mastectomy pain syndrome (PMPS) referred to a tertiary cancer pain clinic between January 2022 and September 2025. The dataset, authored by Morsi Khashan, includes patient-reported measures like the Brief Pain Inventory and Pain Catastrophizing Scale, and classifies pain as nociceptive, neuropathic, or mixed.

Use Cases

• Classifying pain phenotypes (nociceptive, neuropathic, mixed) based on structured clinical assessment data.
• Identifying risk factors for mixed pain presentations based on variables like multiplicity of pain sources and radiotherapy-attributed pain.
• Analyzing the relationship between pain intensity, interference, and catastrophizing scores across different pain phenotypes.

Strengths

• Includes data from 120 patients with a mean age of 57.9 years.
• Pain phenotypes are quantified (40.8% nociceptive, 25.0% neuropathic, 34.2% mixed).
• Analysis includes adjusted odds ratios for factors associated with mixed pain (e.g., OR 49.96 for multiple pain sources).
• Data is licensed under CC-BY-4.0, allowing for reuse with attribution.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The observational design and model limitations suggest results are hypothesis-generating.
• The dataset is very small (27.9 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Retrospective analysis of prospectively maintained data from a tertiary cancer-related pain clinic.

Time Range

January 2022 to September 2025

Freshness

Last updated 2026-04-15 04:36:41.

Geography

null